{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:59Z","timestamp":1793412059224,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T00:00:00Z","timestamp":1445904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The blood-based diagnosis has a potential to provide an alternative approach for easy diagnosis of Alzheimer\u2019s disease (AD) with less invasiveness and low-cost. However, present blood-based AD diagnosis mainly focuses on measuring the plasma A\u03b2 level because no other biomarkers are found to possess evident transport mechanisms to pass the blood-brain barrier. In order to avoid diagnosing non-demented individuals with A\u03b2 abnormality, finding additional biomarkers to supplement plasma A\u03b2 is essential. In this study, we introduce potential neurodegenerative biomarkers for blood-based diagnosis. We observed severe splenomegaly and structural destruction in the spleen with significantly decreased B lymphocytes in senile APP<jats:sub>swe<\/jats:sub>, PS1<jats:sub>M146V<\/jats:sub> and Tau<jats:sub>P301L<\/jats:sub> transgenic mice. We also found that inflammatory cytokines associated with splenic dysfunction were altered in the plasma of these mice. These findings suggest potential involvement of the splenic dysfunction in AD and the importance of biomarker level alterations in the plasma as putative diagnostic targets for AD.<\/jats:p>","DOI":"10.1038\/srep15703","type":"journal-article","created":{"date-parts":[[2015,10,27]],"date-time":"2015-10-27T10:43:33Z","timestamp":1445942613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Abnormalities of plasma cytokines and spleen in senile APP\/PS1\/Tau transgenic mouse model"],"prefix":"10.1038","volume":"5","author":[{"given":"Seung-Hoon","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Jisoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YoungSoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,27]]},"reference":[{"key":"BFsrep15703_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/archneur.1994.00540190056015","volume":"51","author":"HC Chui","year":"1994","unstructured":"Chui, H. C., Lyness, S. A., Sobel, E. & Schneider, L. S. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer\u2019s disease. Arch Neurol 51, 676\u2013681 (1994).","journal-title":"Arch Neurol"},{"key":"BFsrep15703_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/089198879300600410","volume":"6","author":"TP Miller","year":"1993","unstructured":"Miller, T. P., Tinklenberg, J. R., Brooks, J. O., 3rd, Fenn, H. H. & Yesavage, J. A. Selected psychiatric symptoms associated with rate of cognitive decline in patients with Alzheimer\u2019s disease. J Geriatr Psychiatry Neurol 6, 235\u2013238 (1993).","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"BFsrep15703_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/gps.2550","volume":"26","author":"K Karttunen","year":"2011","unstructured":"Karttunen, K. et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer\u2019s disease. Int J Geriatr Psychiatry 26, 473\u2013482, 10.1002\/gps.2550 (2011).","journal-title":"Int J Geriatr Psychiatry"},{"key":"BFsrep15703_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/JAD-2012-111886","volume":"29","author":"G Spalletta","year":"2012","unstructured":"Spalletta, G., Girardi, P., Caltagirone, C. & Orfei, M. D. Anosognosia and neuropsychiatric symptoms and disorders in mild Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 29, 761\u2013772, 10.3233\/JAD-2012-111886 (2012).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep15703_CR5","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/gerona\/61.7.755","volume":"61","author":"D de Jong","year":"2006","unstructured":"de Jong, D., Jansen, R. W., Kremer, B. P. & Verbeek, M. M. Cerebrospinal fluid amyloid beta42\/phosphorylated tau ratio discriminates between Alzheimer\u2019s disease and vascular dementia. J Gerontol A Biol Sci Med Sci 61, 755\u2013758 (2006).","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"BFsrep15703_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1373\/clinchem.2009.130518","volume":"56","author":"C Mulder","year":"2010","unstructured":"Mulder, C. et al. Amyloid-beta(1-42), total tau and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56, 248\u2013253, 10.1373\/clinchem.2009.130518 (2010).","journal-title":"Clin Chem"},{"key":"BFsrep15703_CR7","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/archneur.59.11.1729","volume":"59","author":"M Riemenschneider","year":"2002","unstructured":"Riemenschneider, M. et al. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59, 1729\u20131734 (2002).","journal-title":"Arch Neurol"},{"key":"BFsrep15703_CR8","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters, C. L. et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82, 4245\u20134249 (1985).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15703_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price, J. L. & Morris, J. C. Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 45, 358\u2013368 (1999).","journal-title":"Ann Neurol"},{"key":"BFsrep15703_CR10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman, D. S. et al. Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol 62, 1087\u20131095 (2003).","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFsrep15703_CR11","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1212\/01.wnl.0000219668.47116.e6","volume":"66","author":"DA Bennett","year":"2006","unstructured":"Bennett, D. A. et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837\u20131844, 10.1212\/01.wnl.0000219668.47116.e6 (2006).","journal-title":"Neurology"},{"key":"BFsrep15703_CR12","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1212\/01.wnl.0000228230.26044.a4","volume":"67","author":"MA Mintun","year":"2006","unstructured":"Mintun, M. A. et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446\u2013452, 10.1212\/01.wnl.0000228230.26044.a4 (2006).","journal-title":"Neurology"},{"key":"BFsrep15703_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","volume":"132","author":"CR Jack Jr.","year":"2009","unstructured":"Jack, C. R., Jr. et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease. Brain, a journal of neurology 132, 1355\u20131365, 10.1093\/brain\/awp062 (2009).","journal-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease."},{"key":"BFsrep15703_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awn320","volume":"132","author":"EC Mormino","year":"2009","unstructured":"Mormino, E. C. et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain, a journal of neurology 132, 1310\u20131323, 10.1093\/brain\/awn320 (2009).","journal-title":"Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects."},{"key":"BFsrep15703_CR15","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1073\/pnas.0900345106","volume":"106","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer\u2019s disease. Proc Natl Acad Sci USA 106, 6820\u20136825, 10.1073\/pnas.0900345106 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15703_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-122059","volume":"34","author":"DT Chien","year":"2013","unstructured":"Chien, D. T. et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34, 457\u2013468, 10.3233\/JAD-122059 (2013).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep15703_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00259-013-2681-7","volume":"41","author":"VL Villemagne","year":"2014","unstructured":"Villemagne, V. L. et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer\u2019s disease. Eur J Nucl Med Mol Imaging 41, 816\u2013826, 10.1007\/s00259-013-2681-7 (2014).","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"BFsrep15703_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1148\/radiol.2282020915","volume":"228","author":"PM McMahon","year":"2003","unstructured":"McMahon, P. M., Araki, S. S., Sandberg, E. A. & Neumann, P. J. & Gazelle, G. S. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228, 515\u2013522, 10.1148\/radiol.2282020915 (2003).","journal-title":"Radiology"},{"key":"BFsrep15703_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S0074-7742(09)00407-3","volume":"84","author":"JM Noble","year":"2009","unstructured":"Noble, J. M. & Scarmeas, N. Application of pet imaging to diagnosis of Alzheimer\u2019s disease and mild cognitive impairment. Int Rev Neurobiol 84, 133\u2013149, 10.1016\/S0074-7742(09)00407-3 (2009).","journal-title":"Int Rev Neurobiol"},{"key":"BFsrep15703_CR20","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/archneurol.2012.1282","volume":"69","author":"JD Doecke","year":"2012","unstructured":"Doecke, J. D. et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318\u20131325, 10.1001\/archneurol.2012.1282 (2012).","journal-title":"Arch Neurol"},{"key":"BFsrep15703_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2010.1995","volume":"305","author":"K Yaffe","year":"2011","unstructured":"Yaffe, K. et al. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. Jama 305, 261\u2013266, 10.1001\/jama.2010.1995 (2011).","journal-title":"Jama"},{"key":"BFsrep15703_CR22","first-page":"75","volume":"29","author":"A Baranowska-Bik","year":"2008","unstructured":"Baranowska-Bik, A. et al. Plasma beta amyloid and cytokine profile in women with Alzheimer\u2019s disease. Neuro Endocrinol Lett 29, 75\u201379 (2008).","journal-title":"Neuro Endocrinol Lett"},{"key":"BFsrep15703_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jalz.2014.05.1749","volume":"10","author":"A Hye","year":"2014","unstructured":"Hye, A. et al. Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10, 799\u2013807 e792, 10.1016\/j.jalz.2014.05.1749 (2014).","journal-title":"Alzheimers Dement"},{"key":"BFsrep15703_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nm.3466","volume":"20","author":"M Mapstone","year":"2014","unstructured":"Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415\u2013418, 10.1038\/nm.3466 (2014).","journal-title":"Nat Med"},{"key":"BFsrep15703_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo, S. et al. Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409\u2013421 (2003).","journal-title":"Neuron"},{"key":"BFsrep15703_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.brainres.2010.06.011","volume":"1348","author":"R Sterniczuk","year":"2010","unstructured":"Sterniczuk, R., Antle, M. C., Laferla, F. M. & Dyck, R. H. Characterization of the 3xTg-AD mouse model of Alzheimer\u2019s disease: part 2. Behavioral and cognitive changes. Brain Res 1348, 149\u2013155, 10.1016\/j.brainres.2010.06.011 (2010).","journal-title":"Brain Res"},{"key":"BFsrep15703_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.brainres.2010.05.013","volume":"1348","author":"R Sterniczuk","year":"2010","unstructured":"Sterniczuk, R., Dyck, R. H., Laferla, F. M. & Antle, M. C. Characterization of the 3xTg-AD mouse model of Alzheimer\u2019s disease: part 1. Circadian changes. Brain Res 1348, 139\u2013148, 10.1016\/j.brainres.2010.05.013 (2010).","journal-title":"Brain Res"},{"key":"BFsrep15703_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3233\/JAD-131490","volume":"39","author":"M Marchese","year":"2014","unstructured":"Marchese, M. et al. Autoimmune manifestations in the 3xTg-AD model of Alzheimer\u2019s disease. J Alzheimers Dis 39, 191\u2013210, 10.3233\/JAD-131490 (2014).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep15703_CR29","doi-asserted-by":"publisher","first-page":"5540","DOI":"10.1073\/pnas.0912675107","volume":"107","author":"WJ Chae","year":"2010","unstructured":"Chae, W. J. et al. Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis. Proc Natl Acad Sci USA 107, 5540\u20135544, 10.1073\/pnas.0912675107 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFsrep15703_CR30","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1084\/jem.20101823","volume":"208","author":"MP Boldin","year":"2011","unstructured":"Boldin, M. P. et al. miR-146a is a significant brake on autoimmunity, myeloproliferation and cancer in mice. J Exp Med 208, 1189\u20131201, 10.1084\/jem.20101823 (2011).","journal-title":"J Exp Med"},{"key":"BFsrep15703_CR31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.15252\/embr.201439505","volume":"16","author":"NC Walsh","year":"2015","unstructured":"Walsh, N. C. et al. LKB1 inhibition of NF-kappaB in B cells prevents T follicular helper cell differentiation and germinal center formation. EMBO Rep 16, 753\u2013768, 10.15252\/embr.201439505 (2015).","journal-title":"EMBO Rep"},{"key":"BFsrep15703_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ana.20730","volume":"59","author":"AM Fagan","year":"2006","unstructured":"Fagan, A. M. et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512\u2013519, 10.1002\/ana.20730 (2006).","journal-title":"Ann Neurol"},{"key":"BFsrep15703_CR33","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.biopsych.2009.01.027","volume":"65","author":"T Grimmer","year":"2009","unstructured":"Grimmer, T. et al. Beta amyloid in Alzheimer\u2019s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry 65, 927\u2013934, 10.1016\/j.biopsych.2009.01.027 (2009).","journal-title":"Biol Psychiatry"},{"key":"BFsrep15703_CR34","doi-asserted-by":"publisher","first-page":"226ra230","DOI":"10.1126\/scitranslmed.3007901","volume":"6","author":"AM Fagan","year":"2014","unstructured":"Fagan, A. M. et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer\u2019s disease. Sci Transl Med 6, 226ra230, 10.1126\/scitranslmed.3007901 (2014).","journal-title":"Sci Transl Med"},{"key":"BFsrep15703_CR35","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/nm1653","volume":"13","author":"S Ray","year":"2007","unstructured":"Ray, S. et al. Classification and prediction of clinical Alzheimer\u2019s diagnosis based on plasma signaling proteins. Nat Med 13, 1359\u20131362, 10.1038\/nm1653 (2007).","journal-title":"Nat Med"},{"key":"BFsrep15703_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JAD-2010-100852","volume":"22","author":"S Subramanian","year":"2010","unstructured":"Subramanian, S. et al. CCR6: a biomarker for Alzheimer\u2019s-like disease in a triple transgenic mouse model. J Alzheimers Dis 22, 619\u2013629, 10.3233\/JAD-2010-100852 (2010).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep15703_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.yexmp.2008.10.006","volume":"86","author":"S Levine","year":"2009","unstructured":"Levine, S., Saltzman, A., Levy, E. & Ginsberg, S. D. Systemic pathology in aged mouse models of Down\u2019s syndrome and Alzheimer\u2019s disease. Exp Mol Pathol 86, 18\u201322, 10.1016\/j.yexmp.2008.10.006 (2009).","journal-title":"Exp Mol Pathol"},{"key":"BFsrep15703_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.clim.2008.01.002","volume":"127","author":"Z Ma","year":"2008","unstructured":"Ma, Z. et al. Accelerated atherosclerosis in ApoE deficient lupus mouse models. Clin Immunol 127, 168\u2013175, 10.1016\/j.clim.2008.01.002 (2008).","journal-title":"Clin Immunol"},{"key":"BFsrep15703_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/2051-5960-1-76","volume":"1","author":"C Duran-Aniotz","year":"2013","unstructured":"Duran-Aniotz, C., Morales, R., Moreno-Gonzalez, I., Hu, P. P. & Soto, C. Brains from non-Alzheimer\u2019s individuals containing amyloid deposits accelerate Abeta deposition in vivo. Acta Neuropathol Commun 1, 76, 10.1186\/2051-5960-1-76 (2013).","journal-title":"Acta Neuropathol Commun"},{"key":"BFsrep15703_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3233\/JAD-2012-120712","volume":"31","author":"W Zhang","year":"2012","unstructured":"Zhang, W. et al. A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31, 601\u2013612, 10.3233\/JAD-2012-120712 (2012).","journal-title":"J Alzheimers Dis"},{"key":"BFsrep15703_CR41","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1038\/srep06777","volume":"4","author":"SM Cho","year":"2014","unstructured":"Cho, S. M. et al. Correlations of amyloid-beta concentrations between CSF and plasma in acute Alzheimer mouse model. Sci Rep 4, 6777, 10.1038\/srep06777 (2014).","journal-title":"Sci Rep"},{"key":"BFsrep15703_CR42","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1364\/OL.32.001743","volume":"32","author":"Z Li","year":"2007","unstructured":"Li, Z., Herrmann, K. & Pohlenz, F. Lateral scanning confocal microscopy for the determination of in-plane displacements of microelectromechanical systems devices. Optics letters 32, 1743\u20131745 (2007).","journal-title":"Optics letters"},{"key":"BFsrep15703_CR43","doi-asserted-by":"crossref","unstructured":"Liu, L. & Duff, K. A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp, 10.3791\/960 (2008).","DOI":"10.3791\/960"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep15703.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep15703","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep15703.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T13:45:02Z","timestamp":1672926302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep15703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,21]]}},"alternative-id":["BFsrep15703"],"URL":"https:\/\/doi.org\/10.1038\/srep15703","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,27]]},"assertion":[{"value":"19 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15703"}}